Catheter Precision Stock Price, News & Analysis

Catheter Precision (NYSE American: VTAK), a medical device company specializing in cardiac electrophysiology products, has implemented a 1-for-19 reverse stock split effective August 15, 2025. The split will reduce the company's outstanding common shares from 23,316,520 to approximately 1,657,640.

The stock will continue trading under the symbol "VTAK" with a new CUSIP number 74933X708. Proportional adjustments will be made to equity awards, warrants, and other convertible securities. No fractional shares will be issued; instead, stockholders entitled to fractional shares will receive pro-rata proceeds from their sale.

Catheter Precision (NYSE:VTAK), a US-based medical device company, has announced the successful completion of its first LockeT cases in Germany at Zentralklinik Bad Berka, one of Thuringia's largest hospitals.

The medical team has successfully conducted 10 cases using LockeT to close single or multiple punctures with a single device per case. The procedures demonstrated LockeT's versatility by handling sheath sizes ranging from 6F to 17Fr. The company views Germany as a significant European market opportunity, particularly due to its price-conscious nature.

Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology, reported significant growth in Q2 2025. Revenue surged 128% year-over-year to $212,000 and 48% sequentially. The company achieved several milestones, including receiving CE Mark for LockeT and completing strategic acquisitions.

Notable clinical achievements include successful trials demonstrating VIVO's 94% accuracy in non-invasive localization and 83% long-term procedural success. The company formed Kardionav, Inc. for developing implant-based software for ventricular tachyarrhythmia treatment. However, the company reported a net loss of $5.4 million for Q2 2025, with $3.2 million in non-cash charges, and maintained a cash position of $838,000.

Catheter Precision (NYSE:VTAK) announced that the Heart Hospital of New Mexico has achieved a significant milestone by completing 200 ventricular ablation procedures using the company's VIVO system. The Heart Hospital, part of the Lovelace Health system, is New Mexico's only hospital dedicated exclusively to cardiovascular care.

The Lovelace Health system encompasses five hospitals, 33 health care clinics, and seven outpatient therapy clinics with over 300 healthcare providers. The hospital's physician team has published data and facilitated educational initiatives for other physicians regarding the VIVO technology.

Catheter Precision (NYSE:VTAK) has secured its largest purchase order to date for its VIVO product line from Centre Hospitalier Universitaire (CHU) de Rennes in France. The hospital, which serves approximately 500,000 patients annually, performs over 150 ventricular ablations per year, making it one of Europe's largest ventricular ablation centers.

CEO David Jenkins emphasized the strategic importance of partnering with teaching hospitals to introduce their products to physicians early in their careers, which could lead to long-term product adoption.

Catheter Precision (NYSE:VTAK) has announced the formation of a new joint venture called Kardionav to develop advanced AI-powered software for ventricular tachycardia (VT) ablation. The venture combines VTAK's expertise with Chelak iECG to enhance VT treatment outcomes through improved mapping technology.

The ownership structure allocates 56% to VTAK, 33% to Chelak iECG, and 10% to management. Dr. Jie Cheng, founder of Chelak iECG and Clinical Professor at Baylor College of Medicine, will serve as the primary researcher, bringing significant AI and arrhythmia localization expertise to the venture.

The joint venture aims to develop a standalone ventricular mapping system that will integrate vector technology with imaging of conduction channels and velocity calculations. This next-generation technology builds upon VTAK's existing VIVO platform and seeks to address current limitations in VT ablation procedures, including lengthy procedure times and imprecise ablation site targeting.

Catheter Precision (NYSE American: VTAK), a medical device company specializing in electrophysiology products, has issued a statement addressing unusual trading activity in its stock. The company explicitly stated it is unaware of any operational or company-related information that would explain the increased market activity. Management confirmed they are continuing to execute their previously disclosed strategic plans, including actively seeking financing to address their liquidity requirements.

Catheter Precision (VTAK) reported significant growth in LockeT sales for Q2 2025, showing a 200% increase compared to Q2 2024. Several major US hospitals, including Montefiore, Eisenhower Health, and Overland Park Regional Medical Center, are expected to place purchase orders exceeding $100,000 each for LockeT by year-end. Following CE Mark approval for European sales, the company has secured an Italian distributor and is finalizing distribution partnerships in Spain, Portugal, and the UK. A live demonstration of LockeT is scheduled for June 16 at an Italian symposium by a key opinion leader, aimed at increasing product awareness in the new European market.

Catheter Precision (VTAK) has secured its first VIVO product purchase order from Sahlgrenska University Hospital (SUH) in Sweden. SUH, the largest hospital in Sweden, treats 350,000 patients annually and operates the region's largest ventricular ablation program. CEO David Jenkins emphasized the strategic importance of partnering with SUH as a teaching hospital, noting that training new physicians on their products creates future sales opportunities when doctors transition to other institutions. This development marks Catheter Precision's expansion into the Swedish market with their cardiac electrophysiology technology.